

ASX:NRT

NASDAQ:NVGN

Novogen Ltd
(Company)

ABN 37 063 259 754

Capital Structure

Ordinary Shares on
issue:

246 M

Board of Directors

Dr Graham Kelly
Chairman &
Executive Director

Steve Coffey
Non Executive Director

John O'Connor
Non Executive Director

Prof Peter Gunning
Non Executive Director

ASX RELEASE

16 January 2015

EARLY TERMINATION OF FUNDING ARRANGEMENT

16 January 2015, Sydney, Australia: Novogen Limited (ASX:NRT; NASDAQ:NVGN), an Australian/US biotechnology company, today announced that it terminated the Convertible Note Agreement it entered into on 4th July 2013 with Hudson Bay Capital.

The Agreement comprised a maximum of 5 Notes, 4 of which have been exercised by Novogen for the sum of AUD\$6M. The fourth Note was exercised by Novogen in January 2014.

In view of the recent capital-raising effort that has contributed to the Company's current healthy cash position, Novogen will not be seeking to exercise the fifth and final Note.

Novogen wishes to publically acknowledge the assistance of Hudson Bay Capital via this funding agreement in its formative years. These funds have been pivotal over the past 18 months in allowing Novogen to develop its pipeline of four drugs.

About Novogen Limited

Novogen is a public, Australian drug-development company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN'). The Novogen group includes US-based, CanTx Inc, a joint venture company with Yale University.

Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been designed to kill the full heterogeneity of cells within a tumor, including the cancer stem cells. The molecular target is a trans-membrane electron-transfer pump mechanism oncogene that is common to all cancer cells. Cells die by respiratory distress and mitochondrial disintegration.

The ATM compounds target the micro-filament component of the cancer cell's cytoskeleton and have been designed to combine with anti-microtubular drugs (taxanes, vinca alkaloids) to produce comprehensive and fatal destruction of the cancer cell cytoskeleton.

The Company pipeline comprises three SBP drug candidates (TRXE-002, TRXE-009, TRXE-0025) and one ATM drug candidate ('Anisina').

Further information is available on our websites www.novogen.com

For more information please contact:

Corporate Contact

Dr. Graham Kelly
Executive Chairman & CEO Novogen Group
Graham.Kelly@novogen.com
+61 (0) 2 9472 4100

Lionel Mateo
Company Secretary Novogen Group
Lionel.Mateo@novogen.com
+61 (0) 2 9472 4104

Media Enquiries

Cristyn Humphreys
Chief Operating Officer Novogen Group
Cristyn.Humphreys@novogen.com
+61 (0) 2 9472 4111